- Major pharmaceutical companies including Sanofi, Regeneron, Roche, Eli Lilly, Biogen, and Gilead are maintaining alliances and competing across key therapeutic areas like ophthalmology, immunology, and oncology.
- Sanofi, Regeneron, and Bayer are involved in new market developments, including FDA submissions regarding eczema and eye care treatments.
- Regeneron, Bayer, and FDA are involved in the joint development of Eylea HD, following an FDA inspection of a third-party manufacturer.
Regeneron Pharmaceuticals and its team highlighted the strong commercial performance of key products and anticipated decisions regarding EYLEA HD and Libtayo use.
1 report, 1 independent
Updated Aug 13
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Regeneron Pharmaceuticals and its team highlighted the strong commercial performance of key products and anticipated decisions regarding EYLEA HD and Libtayo use.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Regeneron Pharmaceuticals
American pharmaceutical company
- FDA
Related events
- A product was launched in the U.S. market following FDA involvement.
- FDA seeks to ease market restrictions while consumer companies Ferrara and Hershey innovate in premium product lines.
- Mylan is seeking regulatory approval from the FDA for new products and has listed its stock on the Nasdaq exchange.
Coverage
Newest first; wire copies grouped- StockStoryREGN Q2 Deep Dive: New Indications and Pipeline Progress Offset EYLEA Challenges Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales